Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-337-4701
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees102
Next Earnings Date8/5/2019 (Estimated)
OptionableNot Optionable
Neon Therapeutics (NASDAQ:NTGN) Frequently Asked Questions
What is Neon Therapeutics' stock symbol?
Neon Therapeutics trades on the NASDAQ under the ticker symbol "NTGN."
How were Neon Therapeutics' earnings last quarter?
Neon Therapeutics Inc (NASDAQ:NTGN) posted its quarterly earnings data on Monday, May, 13th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by $0.03. View Neon Therapeutics' Earnings History.
When is Neon Therapeutics' next earnings date?
What price target have analysts set for NTGN?
6 brokerages have issued 1 year target prices for Neon Therapeutics' shares. Their predictions range from $10.00 to $23.00. On average, they expect Neon Therapeutics' share price to reach $18.1429 in the next year. This suggests a possible upside of 268.8% from the stock's current price. View Analyst Price Targets for Neon Therapeutics.
What is the consensus analysts' recommendation for Neon Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neon Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neon Therapeutics.
Has Neon Therapeutics been receiving favorable news coverage?
News coverage about NTGN stock has trended positive this week, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neon Therapeutics earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Neon Therapeutics.
Are investors shorting Neon Therapeutics?
Neon Therapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 550,900 shares, an increase of 6.7% from the April 30th total of 516,400 shares. Based on an average trading volume of 156,300 shares, the days-to-cover ratio is presently 3.5 days. Approximately 4.0% of the shares of the stock are sold short. View Neon Therapeutics' Current Options Chain.
Who are some of Neon Therapeutics' key competitors?
Some companies that are related to Neon Therapeutics include Translate Bio (TBIO), DBV TECHNOLOGIE/S (DBVT), Mesoblast (MESO), Scholar Rock (SRRK), BioCardia (BCDA), Replimune Group (REPL), Krystal Biotech (KRYS), Agenus (AGEN), Adaptimmune Therapeutics (ADAP), Gritstone Oncology (GRTS), BioCryst Pharmaceuticals (BCRX), Acorda Therapeutics (ACOR), PDL BioPharma (PDLI), Avrobio (AVRO) and Tcr2 Therapeutics (TCRR).
What other stocks do shareholders of Neon Therapeutics own?
Who are Neon Therapeutics' key executives?
Neon Therapeutics' management team includes the folowing people:
- Mr. Hugh O'Dowd, Pres, CEO & Director (Age 54)
- Dr. Eric S. Lander, Founder & Director (Age 62)
- Dr. Yasir B. Al-Wakeel, Chief Financial Officer (Age 37)
- Dr. Richard Gaynor, Pres of R&D (Age 69)
- Dr. Edward Fritsch Ph.D., Founder and Chief Technology Officer
When did Neon Therapeutics IPO?
(NTGN) raised $101 million in an initial public offering (IPO) on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities served as the underwriters for the IPO and Oppenheimer was co-manager.
Who are Neon Therapeutics' major shareholders?
Neon Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (7.22%), Acadian Asset Management LLC (0.15%), Oppenheimer & Co. Inc. (0.11%), Rhumbline Advisers (0.04%), Harel Insurance Investments & Financial Services Ltd. (0.04%) and Marshall Wace North America L.P. (0.03%). View Institutional Ownership Trends for Neon Therapeutics.
Which major investors are selling Neon Therapeutics stock?
Which major investors are buying Neon Therapeutics stock?
NTGN stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Oppenheimer & Co. Inc., Rhumbline Advisers, Marshall Wace North America L.P. and Harel Insurance Investments & Financial Services Ltd.. View Insider Buying and Selling for Neon Therapeutics.
How do I buy shares of Neon Therapeutics?
Shares of NTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neon Therapeutics' stock price today?
One share of NTGN stock can currently be purchased for approximately $4.92.
How big of a company is Neon Therapeutics?
Neon Therapeutics has a market capitalization of $139.38 million. The company earns $-76,930,000.00 in net income (profit) each year or ($5.54) on an earnings per share basis. Neon Therapeutics employs 102 workers across the globe.View Additional Information About Neon Therapeutics.
What is Neon Therapeutics' official website?
How can I contact Neon Therapeutics?
Neon Therapeutics' mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4701 or via email at [email protected]
MarketBeat Community Rating for Neon Therapeutics (NASDAQ NTGN)
MarketBeat's community ratings are surveys of what our community members think about Neon Therapeutics and other stocks. Vote "Outperform" if you believe NTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
